Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel Free THMO Stock Alerts

ThermoGenesis (THMO) Competitors

ThermoGenesis logo
Compare

THMO vs. HTGMQ, BTTX, EFTR, AFIB, and CMRA

Should you buy ThermoGenesis stock or one of its competitors? ThermoGenesis's main competitors and comparable companies include HTG Molecular Diagnostics (HTGMQ), Better Therapeutics (BTTX), eFFECTOR Therapeutics (EFTR), Acutus Medical (AFIB), and Comera Life Sciences (CMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does ThermoGenesis compare to HTG Molecular Diagnostics?

ThermoGenesis (NASDAQ:THMO) and HTG Molecular Diagnostics (NASDAQ:HTGMQ) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled HTG Molecular Diagnostics'average media sentiment score.

Company Overall Sentiment
ThermoGenesis Neutral
HTG Molecular Diagnostics Neutral

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
HTG Molecular Diagnostics N/A N/A N/A

5.8% of ThermoGenesis shares are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by insiders. Comparatively, 2.6% of HTG Molecular Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ThermoGenesis has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, HTG Molecular Diagnostics has a beta of 3, indicating that its stock price is 200% more volatile than the broader market.

ThermoGenesis has higher revenue and earnings than HTG Molecular Diagnostics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
HTG Molecular Diagnostics$6.37M0.00-$21.59MN/AN/A

Summary

ThermoGenesis beats HTG Molecular Diagnostics on 5 of the 6 factors compared between the two stocks.

How does ThermoGenesis compare to Better Therapeutics?

ThermoGenesis (NASDAQ:THMO) and Better Therapeutics (NASDAQ:BTTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Company Net Margins Return on Equity Return on Assets
ThermoGenesisN/A N/A N/A
Better Therapeutics N/A N/A N/A

ThermoGenesis has higher revenue and earnings than Better Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A

5.8% of ThermoGenesis shares are owned by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by insiders. Comparatively, 51.4% of Better Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ThermoGenesis has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.

Company Overall Sentiment
ThermoGenesis Neutral
Better Therapeutics Neutral

Summary

ThermoGenesis beats Better Therapeutics on 5 of the 7 factors compared between the two stocks.

How does ThermoGenesis compare to eFFECTOR Therapeutics?

eFFECTOR Therapeutics (NASDAQ:EFTR) and ThermoGenesis (NASDAQ:THMO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

eFFECTOR Therapeutics has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market. Comparatively, ThermoGenesis has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of ThermoGenesis shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Comparatively, 78.0% of ThermoGenesis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
ThermoGenesis Neutral

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
ThermoGenesis N/A N/A N/A

ThermoGenesis has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A

Summary

ThermoGenesis beats eFFECTOR Therapeutics on 5 of the 7 factors compared between the two stocks.

How does ThermoGenesis compare to Acutus Medical?

Acutus Medical (NASDAQ:AFIB) and ThermoGenesis (NASDAQ:THMO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Acutus Medical has a beta of 5.73, suggesting that its stock price is 473% more volatile than the broader market. Comparatively, ThermoGenesis has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

ThermoGenesis has higher revenue and earnings than Acutus Medical. Acutus Medical is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A

56.9% of Acutus Medical shares are owned by institutional investors. Comparatively, 5.8% of ThermoGenesis shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by insiders. Comparatively, 78.0% of ThermoGenesis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Acutus Medical's average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
ThermoGenesis Neutral

ThermoGenesis has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. ThermoGenesis' return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
ThermoGenesis N/A N/A N/A

Summary

ThermoGenesis beats Acutus Medical on 7 of the 10 factors compared between the two stocks.

How does ThermoGenesis compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and ThermoGenesis (NASDAQ:THMO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
ThermoGenesis Neutral

5.8% of ThermoGenesis shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by insiders. Comparatively, 78.0% of ThermoGenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
ThermoGenesis N/A N/A N/A

Comera Life Sciences has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, ThermoGenesis has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

ThermoGenesis has higher revenue and earnings than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A

Summary

ThermoGenesis beats Comera Life Sciences on 6 of the 7 factors compared between the two stocks.

Get ThermoGenesis News Delivered to You Automatically

Sign up to receive the latest news and ratings for THMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

THMO vs. The Competition

Export
MetricThermoGenesisLaboratory apparatus & furniture IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$1K$7.16B$14.31B
Dividend YieldN/AN/A2.57%11.71%
P/E Ratio0.00N/A273.3025.37
Price / SalesN/A0.00617.1274.54
Price / CashN/AN/A28.4234.96
Price / BookN/AN/A10.426.24
Net Income-$17.98M-$17.98M$3.49B$358.08M

ThermoGenesis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
THMO
ThermoGenesis
N/AN/AN/AN/A$1K$9.61MN/A40
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/A$0.00$6.37MN/A90
BTTX
Better Therapeutics
N/AN/AN/AN/A$4KN/AN/A40
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/AN/A$4KN/AN/A10
AFIB
Acutus Medical
N/A$0.00
flat		N/A-90.0%$3K$7.16MN/A340

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:THMO) was last updated on 9/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel